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Purpose: This study investigated clinical outcomes of the combined method of scraping, coagulation, and
subconjunctival bevacizumab for the treatment of corneal neovascularization (NV) in penetrating
keratoplasty (PKP).
Methods: This study included patients undergoing PKP who were diagnosed with bullous keratopathy
with dense subepithelial scarring that was not suitable for Descemet’s stripping automated endothelial
keratoplasty. Corneal NV was treated by scraping the corneal epithelium and lightly coagulating the
superﬁcial corneal stromal NV combined with subconjunctival bevacizumab injection at the end of
surgery. Patients without corneal NV were used as the control group.
Results: There were six patients with vascularized corneas in the study group and three patients without
vascularized corneas in the control group. The original corneal NV in the study group disappeared in all
patients after surgery. Three of the six (50%) study patients experienced recurrent corneal NV. One of the
three (33%) control patients developed corneal NV. These patients had no corneal NV recurrences over
the next 6 months after repeat treatment. In both groups, no graft failure or chronic epithelial defects
occurred.
Conclusion: The combination of scraping the corneal epithelium, coagulating the superﬁcial corneal
stromal NV and the feeding vessels in the sclera after peritomy, and subconjunctival bevacizumab
injection is an effective method to treat corneal NV in corneal transplantation for bullous keratopathy.
Copyright  2011, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Long-standing bullous keratopathy usually induces extensive
corneal neovascularization (NV), and corneal transplantation in
bullous keratopathy patients with extensive corneal NV carries
a high risk of graft rejection.1,2 There are various methods available
for treating corneal NV before corneal transplantation, such as
argon laser photocoagulation, photodynamic therapy with
different photosensitizers, and epithelial debridement.3,4
However, these therapies are often associated with thermal or
mechanical damage to the cornea, which activates the inﬂamma-
tory cascade and leads to an upregulation of vascular endothelial
growth factor (VEGF).4 Hence, the aforementioned therapies haveogy, China Medical University
ai).
e Ophthalmologic Society of Taiwaa high rate of vessel regeneration in the corneal stroma that is
difﬁcult to control.
Treatment using angiogenic inhibitors has become a novel
method for the management of both superﬁcial and stromal corneal
NV.5e7 Bevacizumab is a full-length humanized murine monoclonal
antibody against all types of VEGF. It is approved to treat metastatic
colorectal cancer,8 diabetic retinopathy,9,10 choroidal NV in patho-
logic myopia,11, and exudative age-related macular degener-
ation.12e14 Recently, the effects of subconjunctival injection15e18 and
topical application 19e21 of bevacizumab on inhibition of corneal NV
have been reported. However, in humans, bevacizumab treatment
either in the form of drops22e24 or by subconjunctival administra-
tion15,25,26 was either ineffective or led to only partial regression of
the corneal NV. With regard to patients with a previously rejected
vascularized graft, bevacizumab treatment resulted in little change
in the number and caliber of blood vessels.26 The lack of results in
these cases was attributed to the varying levels of VEGF expression
in established and actively growing vessels.26 Bevacizumab had then. Published by Elsevier Taiwan LLC. All rights reserved.
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was ineffective against previously established blood vessels.27
Combined mechanical or thermal methods to destroy estab-
lished NV together with subconjunctival bevacizumab to stop new
vessel growth is a reasonable method to treat corneal NV. More-
over, in animal models, bevacizumab signiﬁcantly inhibited NV
when administered immediately after limbal injury but provided
less signiﬁcant regression of established NV.18,27 Therefore,
destroying NV and administering bevacizumab injections should be
performed simultaneously to achieve the optimal anti-neovascular
effect.
Combination therapy using bevacizumab has been previously
reported in three cases. Qian et al28 scraped the corneal epithelium
and injected bevacizumab subconjunctivally in a case of peripheral
ulcerative keratitis in a patient with Terrien marginal degeneration,
and Gerten4 used argon laser coagulation and bevacizumab injec-
tions in two corneal transplants. The results revealed that this type
of therapy was safe and effective.
Owing to the difﬁculties in performing intraoperative corneal
epithelial scraping or postoperative argon laser coagulation to
destroy the corneal stromal NV and the feeding vessels in the
conjunctiva and sclera, we developed a method to eliminate the
vessels of vascularized bullous keratopathy in corneal trans-
plantation. We scraped the corneal epithelium in the corneal NV
area and then coagulated the superﬁcial corneal stromal NV in the
peripheral cornea and the feeding vessels in the conjunctiva and
sclera. After corneal transplant, we injected bevacizumab subcon-
junctivally. To conclude, this method of destroying and preventing
corneal NV in corneal transplantation was evaluated.
2. Patients and methods
A 1-year clinical trial was designed that included all qualifying
bullous keratopathy patients undergoing corneal transplantation.
One doctor (Y.-Y.T.) performed all corneal transplantations in this
clinical trial. We performed penetrating keratoplasty (PKP) for
those with dense subepithelial scarring, which rendered them poor
candidates for Descemet’s stripping automated endothelial kera-
toplasty (DSAEK). Patients with vascularized corneas were included
in the study group and patients without vascularized corneas were
included in the control group.
The study group underwent the following procedure: the
corneal epithelium in the corneal NV area was scraped and the
superﬁcial corneal stromal NV in the peripheral cornea was lightly
coagulated. After partial peritomy, the feeding vessels of all corneal
stromal NV in the sclera were coagulated. During corneal and
scleral coagulation, the limbus was spared. If the corneal epithelial
NV was extensive, we coagulated the epithelial NV to decrease
hemorrhage before scraping the corneal epithelium in the corneal
NV area. In the control group, the corneal epithelium was kept
intact. At the end of surgery, 0.3 mL subconjunctival bevacizumab
injection was administered to the study group.Table 1
Patients’ Character and Average Scores Before and After PKP
Patient No. Age Sex Disease Preoperative
Extent Centricity
1 45 M Failed PKP 6 2
2 42 F PBK 4 1.5
3 34 F Failed PKP 4 1.5
4 69 M Failed PKP 5 2
5 45 M Failed PKP 8 3
6 47 M Failed PKP 3 1,5After corneal transplantation, all patients stayed in the hospital
for 4e5 days andwere followed up at 1, 2, 3, 4, 6, and 8weeks and 3,
4, 5, and 6 months postoperatively. After 6 months, follow-up
examinations were performed every 2e3 months.
At each visit, two digital corneal photographs were taken using
a Topcon DC-1 digital camera attached to the slit-lamp microscope.
The photographswere graded by one observer for extent, centricity,
and density of corneal vascularization (as previously described by
Bahar et al15). Brieﬂy, extent was deﬁned according to the number
of clock hours affected by NV (score 1e12). Centricity was deﬁned
as the distance the new vessels extended from the limbus towards
the visual axis. Density was graded 1e4 according to the density of
NV. Each picture was scored by a second investigator according to
the changes in NV extent, centricity, and density before and after
surgery.
During follow-up, if NV was invading the cornea by more than 1
mm, the patient received another treatment of epithelial scraping,
NV coagulation, and 0.3 mL subconjunctival bevacizumab injection.
Efﬁcacy of the anti-corneal NV method was evaluated as the
recurrence rate of corneal NV and the number of times the patients
required retreatment during the postoperative 6 months.
In accordancewith the Declaration of Helsinki, the experimental
status of the method and off-label use of bevacizumab was
explained to all patients, following which, informed patient
consent was obtained. Study protocols were approved by an insti-
tutional review board of the China Medical University Hospital.
3. Results
There were nine bullous keratopathy patients included in this
clinical trial. In the study group, there were six patients with vas-
cularized corneas and in the control group there were three
patients without vascularized corneas. Among the six patients in
the study group, there were ﬁve failed PKPs and one pseudophakic
bullous keratopathy (PBK). Patient characteristics and average
scores preoperatively and postoperatively are summarized in
Table 1. There were two PBKs and one failed deep anterior lamellar
keratoplasty in the control group. All of the original corneal NV in
the study group disappeared after surgery (Fig. 1). However, three
of the six (50%) study patients had recurrent corneal NV. Among the
recurrent patients, one occurred at the 6th week and two at the 8th
week of the study. They underwent repeat epithelial scraping,
coagulation, and 0.3 mL subconjunctival bevacizumab injection.
After the booster, there were no further recurrences of corneal NV
in 6 months; however, one of the three patients had an episode of
acute rejection 3 weeks after the booster. The rejection subsided
after topical steroid treatment. One of the three (33%) controls had
corneal NV 2 weeks after PKP and needed treatment of epithelial
scraping, coagulation, and 0.3 mL subconjunctival bevacizumab
injection. The patient had no corneal NV recurrences over the next
6 months. Neither the study nor the control group had graft failure
or chronic epithelial defects.No of injection Postoperative 12 months
Density Extent Centricity Density
2 2 3 0.5 1
1 1 0 0 0
2 1 1 0.5 1
1 2 1 0.5 1
2 2 0 0 0
1 1 0 0 0
Fig. 1. Anterior segment photograph of Patient 5 (failed PKP) before the PKP and the combined procedure (A) and 6 months after the surgery (B). Patient 6 (failed PKP) before the
PKP and the combined procedure (C) and 3 months after the surgery (D).
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Before the application of anti-VEGF therapy, various surgical and
medical treatments were used to counter corneal NV.2e4,28,29
Unfortunately, these treatments did not provide good control of
vessel progression and recurrence. Surgery often activates biolog-
ical mediators of the inﬂammatory cascade and this leads to an
upregulation of VEGF4,30; consequently, such therapies have an
immediate positive effect but are associated with a high rate of
vessel recanalization. Amongmedical treatments available, steroids
remain the treatment of choice to control corneal NV. However,
steroids alone are not always effective and can contribute to
adverse effects, including glaucoma, infection, and cataract
formation.19
Bevacizumab has recently been compared to betamethasone, as
bevacizumab is reported to be effective in the prevention of
formation as well as the regression of major vessels.31 However, the
most prominent effect of bevacizumab is on newly developed or
developing vessels and it is relatively ineffective against previously
established blood vessels.27 Because corneal NV is a chronic and
progressive phenomenon and vessels found at the time of diagnosis
are a mixture of new and old vessels, a combination of surgical
methods in addition to bevacizumab therapy is a reasonable
treatment modality; surgery removes mature vessels, whereas
bevacizumab prevents new vessels from growing.
Moreover, corneal NV is often associated with epithelial and
stromal NV, thus removing the corneal epithelial NV and destroying
the corneal stromal NV and the feeding vessels in the conjunctiva
and sclera is often necessary. Surgical treatments by argon laser
photocoagulation or epithelial scraping are not sufﬁcient for the
removal of stromal NV and feeding vessels in the conjunctiva and
sclera. For these reasons, we scraped the epithelium, coagulated thesuperﬁcial corneal stromal NV, and coagulated the feeding vessels in
the sclera after peritomy. Furthermore, the epithelial defect after
scraping the epithelium allows bevacizumab to easily penetrate the
former NV area.27
Bevacizumab can be used both subconjunctivally and topically
and both routes are reported to exert partial effects15e24; however,
topical application of bevacizumabwas found to cause spontaneous
loss of corneal epithelial integrity and progression of stromal
thinning.23 There were no corneal problems reported with sub-
conjunctival bevacizumab use,15,25,26 and thus subconjunctival
bevacizumab may be a safer option than topical bevacizumab,
particularly in corneal transplantation.
In our study, half of the patients in the PKP study group needed
two rounds of scraping, coagulation, and subconjunctival bev-
acizumab injection. We hypothesized two explanations for this.
Firstly, there were ocular surface complications after PKP, such as
changes in the corneal curvature and tear distribution or stitch-
related inﬂammation. Secondly, various corneal conditions may
affect the number of injections required. Long-term bullous ker-
atopathy results in recurrent corneal epithelial defects, corneal NV,
and subepithelial haze or scar. In bullous keratopathy patients, we
performed PKP only on those with a dense subepithelial scar. A
dense subepithelial scar usually accompanies severe corneal NV,
which may indicate that the cornea requires a larger dose of bev-
acizumab than the 0.3-mL dose used. The three controls in the PKP
group were included because they had bullous keratopathy with
a dense subepithelial scar rarely found without corneal NV.
Of the three PKP study patients with recurrent corneal NV, one
experienced graft rejection even though additional therapy was
performed and there was no apparent NV growth after the second
round of therapy. This may be due to the fact that there is only
a small evident part of corneal NV invasion with slit-lamp
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triggered the immune system prior to a 1-mm invasion of the
cornea. Hence, when performing PKP in bullous keratopathy
patients with intensive corneal NV, a dose >0.3 mL bevacizumab
injection intraoperatively or an early booster prior to 1-mm corneal
invasion postoperatively may be needed because recurrence of
corneal NV will result in a higher chance of rejection.
Theoretically, a control group for this study should comprise
patients with bullous keratopathy with corneal NV who are not
treated with combined scraping, coagulation, and subconjunctival
bevacizumab injection. However, this is not ethically feasible as
corneal transplantation in these patients without removing corneal
NV carries a high risk of graft rejection. Hence, we chose bullous
keratopathy patients without corneal NV as control subjects.
In conclusion, the combined method described in this study
might be an effective alternative to treat corneal NV in PKP for
bullous keratopathy; however, repeated injections of bevacizumab
and long-term follow-up may be needed to validate our study.
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